File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment outcome of rhabdomyosarcoma in Hong Kong Chinese children

TitleTreatment outcome of rhabdomyosarcoma in Hong Kong Chinese children
Authors
KeywordsAdolescent
Child
Rhabdomyosarcoma
Treatment outcome
Issue Date2008
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 2008, v. 14 n. 2, p. 116-123 How to Cite?
AbstractObjectives: To review the treatment outcome of rhabdomyosarcoma in Hong Kong Chinese children. Design: Retrospective review. Setting: University teaching hospital, Hong Kong. Patients: Consecutive cases of rhabdomyosarcoma diagnosed and treated by the Department of Paediatrics and Adolescent Medicine of Queen Mary Hospital between 1989 and 2005. Each patient was staged and treated according to the Intergroup Rhabdomyosarcoma Study guidelines. Main outcome measures: Overall and event-free survival rates, and toxicity data. Results: Of 19 patients (8 males and 11 females), 14 (74%) were younger than 10 years old. The median age at diagnosis was 6 (range, 0.5-17) years. Primary sites of rhabdomyosarcoma included: the head and neck (n=8; 6 classified as cranial parameningeal), genitourinary (3), extremity (3), pelvis (3), and trunk (2). Thirteen (68%) had embryonal and six (32%) had alveolar histology. Two, 2, 9, and 6 were classified as belonging to Intergroup Rhabdomyosarcoma Study groups 1, 2, 3, and 4, respectively. Respective 5-year overall and event-free survival rates of the entire cohort were 49% (95% confidence interval, 26-73%) and 32% (10-55%), with a median follow-up of 3.4 (range, 0.2-16.7) years. In non-metastatic cases (Intergroup Rhabdomyosarcoma Study groups 1-3), the 5-year overall survival rate was 66% (95% confidence interval, 39-93%) and in metastatic cases (group 4) it was 17% (0-46%). The 5-year overall survival rate for patients aged less than 10 years was 60% (95% confidence interval, 33-87%) compared to 20% (0-55%) in those aged 10 years and over. Significant treatment-related toxicities including myelosuppression, infections, peripheral neuropathy, and second cancers were encountered. Conclusions: Treatment outcome of rhabdomyosarcoma in this cohort of Chinese children was less favourable than that reported in international studies. Whilst the main reason could have been related to the high proportion of metastatic cases, also non-metastatic cases faired worse. Improved outcomes may be achieved by advances in multidisciplinary (paediatric oncology, pathology, radiotherapy, and surgery) management and supportive care.
Persistent Identifierhttp://hdl.handle.net/10722/57183
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279
References

 

DC FieldValueLanguage
dc.contributor.authorYuan, XJen_HK
dc.contributor.authorChan, GCFen_HK
dc.contributor.authorChan, SKen_HK
dc.contributor.authorShek, TWHen_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorWei, WIen_HK
dc.contributor.authorHa, SYen_HK
dc.contributor.authorChiang, AKSen_HK
dc.date.accessioned2010-04-12T01:28:45Z-
dc.date.available2010-04-12T01:28:45Z-
dc.date.issued2008en_HK
dc.identifier.citationHong Kong Medical Journal, 2008, v. 14 n. 2, p. 116-123en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/57183-
dc.description.abstractObjectives: To review the treatment outcome of rhabdomyosarcoma in Hong Kong Chinese children. Design: Retrospective review. Setting: University teaching hospital, Hong Kong. Patients: Consecutive cases of rhabdomyosarcoma diagnosed and treated by the Department of Paediatrics and Adolescent Medicine of Queen Mary Hospital between 1989 and 2005. Each patient was staged and treated according to the Intergroup Rhabdomyosarcoma Study guidelines. Main outcome measures: Overall and event-free survival rates, and toxicity data. Results: Of 19 patients (8 males and 11 females), 14 (74%) were younger than 10 years old. The median age at diagnosis was 6 (range, 0.5-17) years. Primary sites of rhabdomyosarcoma included: the head and neck (n=8; 6 classified as cranial parameningeal), genitourinary (3), extremity (3), pelvis (3), and trunk (2). Thirteen (68%) had embryonal and six (32%) had alveolar histology. Two, 2, 9, and 6 were classified as belonging to Intergroup Rhabdomyosarcoma Study groups 1, 2, 3, and 4, respectively. Respective 5-year overall and event-free survival rates of the entire cohort were 49% (95% confidence interval, 26-73%) and 32% (10-55%), with a median follow-up of 3.4 (range, 0.2-16.7) years. In non-metastatic cases (Intergroup Rhabdomyosarcoma Study groups 1-3), the 5-year overall survival rate was 66% (95% confidence interval, 39-93%) and in metastatic cases (group 4) it was 17% (0-46%). The 5-year overall survival rate for patients aged less than 10 years was 60% (95% confidence interval, 33-87%) compared to 20% (0-55%) in those aged 10 years and over. Significant treatment-related toxicities including myelosuppression, infections, peripheral neuropathy, and second cancers were encountered. Conclusions: Treatment outcome of rhabdomyosarcoma in this cohort of Chinese children was less favourable than that reported in international studies. Whilst the main reason could have been related to the high proportion of metastatic cases, also non-metastatic cases faired worse. Improved outcomes may be achieved by advances in multidisciplinary (paediatric oncology, pathology, radiotherapy, and surgery) management and supportive care.en_HK
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsHong Kong Medical Journal. Copyright © Hong Kong Medical Association.en_HK
dc.subjectAdolescenten_HK
dc.subjectChilden_HK
dc.subjectRhabdomyosarcomaen_HK
dc.subjectTreatment outcomeen_HK
dc.subject.meshRhabdomyosarcoma - mortality - pathology - therapyen_HK
dc.subject.meshSoft Tissue Neoplasms - mortality - pathology - therapyen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.subject.meshCombined Modality Therapyen_HK
dc.subject.meshDisease Progressionen_HK
dc.titleTreatment outcome of rhabdomyosarcoma in Hong Kong Chinese childrenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=14&issue=2&spage=116&epage=123&date=2008&atitle=Treatment+outcome+of+rhabdomyosarcoma+in+Hong+Kong+Chinese+childrenen_HK
dc.identifier.emailChan, GCF: gcfchan@hkucc.hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.emailChiang, AKS: chiangak@hkucc.hku.hken_HK
dc.identifier.authorityChan, GCF=rp00431en_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.identifier.authorityChiang, AKS=rp00403en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid18382018en_HK
dc.identifier.scopuseid_2-s2.0-47249083419en_HK
dc.identifier.hkuros139492-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-47249083419&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue2en_HK
dc.identifier.spage116en_HK
dc.identifier.epage123en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridYuan, XJ=23487389200en_HK
dc.identifier.scopusauthoridChan, GCF=16160154400en_HK
dc.identifier.scopusauthoridChan, SK=24472757900en_HK
dc.identifier.scopusauthoridShek, TWH=7005479861en_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK
dc.identifier.scopusauthoridHa, SY=7202501115en_HK
dc.identifier.scopusauthoridChiang, AKS=7101623534en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats